[HTML][HTML] Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label …
ZF Udwadia, P Singh, H Barkate, S Patil… - International Journal of …, 2021 - Elsevier
Objective To assess the efficacy and safety of favipiravir in adults with mild-to-moderate
coronavirus disease 2019 (COVID-19). Methods In this randomized, open-label, parallel …
coronavirus disease 2019 (COVID-19). Methods In this randomized, open-label, parallel …
[HTML][HTML] Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label …
ZF Udwadia, P Singh, H Barkate, S Patil… - … Journal of Infectious …, 2021 - ncbi.nlm.nih.gov
Objective To assess the efficacy and safety of favipiravir in adults with mild-to-moderate
coronavirus disease 2019 (COVID-19). Methods In this randomized, open-label, parallel …
coronavirus disease 2019 (COVID-19). Methods In this randomized, open-label, parallel …
Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label …
ZF Udwadia, P Singh, H Barkate, S Patil, S Rangwala… - 2021 - cabidigitallibrary.org
Objective: To assess the efficacy and safety of favipiravir in adults with mild-to-moderate
coronavirus disease 2019 (COVID-19). Methods: In this randomized, open-label, parallel …
coronavirus disease 2019 (COVID-19). Methods: In this randomized, open-label, parallel …
Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label …
ZF Udwadia, P Singh, H Barkate… - … publication of the …, 2021 - pubmed.ncbi.nlm.nih.gov
Objective To assess the efficacy and safety of favipiravir in adults with mild-to-moderate
coronavirus disease 2019 (COVID-19). Methods In this randomized, open-label, parallel …
coronavirus disease 2019 (COVID-19). Methods In this randomized, open-label, parallel …
[PDF][PDF] Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label …
ZF Udwadia, P Singh, H Barkate, S Patil… - International Journal of …, 2021 - pharmedu.ru
Objective: To assess the efficacy and safety of favipiravir in adults with mild-to-moderate
coronavirus disease 2019 (COVID-19). Methods: In this randomized, open-label, parallel …
coronavirus disease 2019 (COVID-19). Methods: In this randomized, open-label, parallel …
Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label …
ZF Udwadia, P Singh, H Barkate, S Patil… - … Journal of Infectious …, 2020 - europepmc.org
Objective To assess the efficacy and safety of favipiravir in adults with mild-to-moderate
coronavirus disease 2019 (COVID-19). Methods In this randomized, open-label, parallel …
coronavirus disease 2019 (COVID-19). Methods In this randomized, open-label, parallel …
[HTML][HTML] Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label …
ZF Udwadia, P Singh, H Barkate, S Patil… - International Journal of …, 2021 - ijidonline.com
Objective To assess the efficacy and safety of favipiravir in adults with mild-to-moderate
coronavirus disease 2019 (COVID-19). Methods In this randomized, open-label, parallel …
coronavirus disease 2019 (COVID-19). Methods In this randomized, open-label, parallel …
[引用][C] Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label …
ZF Udwadia, P Singh, H Barkate, S Patil… - International Journal of …, 2021 - cir.nii.ac.jp
Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate
COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial | CiNii …
COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial | CiNii …
[PDF][PDF] Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label …
ZF Udwadia, P Singh, H Barkate, S Patil… - International Journal of …, 2021 - academia.edu
Objective: To assess the efficacy and safety of favipiravir in adults with mild-to-moderate
coronavirus disease 2019 (COVID-19). Methods: In this randomized, open-label, parallel …
coronavirus disease 2019 (COVID-19). Methods: In this randomized, open-label, parallel …
Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label …
ZF Udwadia, P Singh, H Barkate… - … publication of the …, 2021 - pubmed.ncbi.nlm.nih.gov
Objective To assess the efficacy and safety of favipiravir in adults with mild-to-moderate
coronavirus disease 2019 (COVID-19). Methods In this randomized, open-label, parallel …
coronavirus disease 2019 (COVID-19). Methods In this randomized, open-label, parallel …